Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances
カートのアイテムが多すぎます
カートに追加できませんでした。
ウィッシュリストに追加できませんでした。
ほしい物リストの削除に失敗しました。
ポッドキャストのフォローに失敗しました
ポッドキャストのフォロー解除に失敗しました
Gwen Nichols speaks with Saad Usmani on CAR-T therapy advances
-
ナレーター：
-
著者：
このコンテンツについて
Saad Usmani, MD, of Memorial Sloan Kettering Cancer Center in New York, and Gwen Nichols, MD, CMO of the Leukemia & Lymphoma Society discuss recent chimeric antigen receptor (CAR)-T cell therapy advancements and the current state of blood cancer research.
Recent trials have shown cures in pediatric acute lymphoblastic leukemia. In myeloma, there has been an “amazing number of advances” by integrating multiple therapies, Dr. Nichols said.
The impact of CAR-T is broadening, paving the way for potential cures in other blood cancers and diseases, she said during the recording.
“We’re curing not only children with leukemia, but now other diseases,” Dr. Nichols said, but warned that research funding cuts could stall young scientists and US innovation.
“The US was the place for great research… people are leaving, and that brain drain will be real,” she warned on the podcast.